Clinical Trial

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-14.
Status change: Not Yet Recruiting → Recruiting 2026-04-13
Trial Details
NCT Number NCT07289477
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Enrollment 9 participants
Start Date 2026-01-05
Primary Completion 2027-10 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-14